Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Inclusion Criteria: * Written informed consent * Females; 18 years of age or greater * Histologically proven invasive breast cancer * American Joint Committee on Cancer (AJCC) clinical stage IIA - IIIB * Tumor size greater than 10 millimeters * HER2 positive * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Estrogen receptor (ER) positive or negative * Ejection fraction greater than or equal to lower limit of normal for the institution by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) * Less than or equal to Grade 1 neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 * Planned lumpectomy or mastectomy * Eligible for radiation therapy * No prior treatment for invasive breast cancer * Adequate organ system function per protocol as determined within 7 days prior to first dose of study treatment * Women of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study treatment and must agree to use adequate contraception methods during study treatment and for a minimum of 6 months following trastuzumab discontinuation * Female subjects who are lactating should discontinue nursing prior to the first dose of study treatment and should refrain from nursing throughout the treatment period Exclusion Criteria: * Fine needle cytology only without other histologic evidence of invasive breast cancer * Inflammatory breast cancer * AJCC clinical stage T1a-b breast cancer (primary tumor less than or equal to 10 millimeters) * Evidence of metastatic disease * HER2 negative * Ejection fraction less than lower limit of normal for the institution by ECHO or MUGA * Corrected QT interval greater than 480 milliseconds * Pre-existing cardiac dysfunction * Prior history of invasive cancer within the past 3 years * Synchronous bilateral breast cancer * Pre-existing CTCAE v4.0 Grade 2 or greater neuropathy * Hypersensitivity to halichondrin B or halichondrin B chemical derivative * History of severe allergic reactions to cisplatin or other platinum containing compounds, or mannitol * Mild, moderate, or severe hepatic impairment * Moderate or severe renal impairment * Hypokalemia or hypomagnesemia if it cannot be corrected prior to the first dose of study treatment * Organ allografts requiring immunosuppression * Known positive human immunodeficiency virus (HIV) status * Prior major surgery within 28 days prior to the first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer * Minor surgery or radiation therapy within 14 days prior to the first dose of study treatment * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures